loading page

Variation in clinical practice guidelines for use of palivizumab in preventing severe respiratory syncytial viral (RSV) disease in high-risk infants
  • +4
  • Eunice Stiboy,
  • Mei Chan,
  • Md Saiful Islam,
  • Gemma Saravanos L,
  • Kei Lui,
  • Adam Jaffe,
  • Nusrat Homaira
Eunice Stiboy
The University of Sydney School of Public Health

Corresponding Author:eunice.stiboy@sydney.edu.au

Author Profile
Mei Chan
The University of Sydney Children's Hospital Westmead Clinical School
Author Profile
Md Saiful Islam
National Centre for Epidemiology and Population Health
Author Profile
Gemma Saravanos L
The University of Sydney Children's Hospital Westmead Clinical School
Author Profile
Kei Lui
The University of Sydney School of Public Health
Author Profile
Adam Jaffe
The University of Sydney Children's Hospital Westmead Clinical School
Author Profile
Nusrat Homaira
The University of Sydney Children's Hospital Westmead Clinical School
Author Profile

Abstract

Background: Uniformity and compliance with clinical practice guidelines (CPGs) for use of palivizumab in preventing severe RSV infection in Australian high-risk infants remain unclear. Methods: An online survey was conducted across the Australian and New Zealand Neonatal Network (ANZNN) to determine clinical practices around palivizumab. A literature search was also performed to identify and compare national and international guidelines. Results: Sixty-five of 422 ANZNN members completed the survey. Respondents included 61 senior medical staff of consultants/staff specialists (78%) and four nursing staff (6%). Infants most likely to be recommended palivizumab included preterm infants born <29 weeks gestational age (GA) (30%), children with chronic lung diseases (CLD) born <32 weeks GA (40%), and with hemodynamically significant heart disease (35%). Many respondents (53%) stated that CPGs for palivizumab were developed locally. Twenty guidelines (10 international and 10 domestic) were obtained in total; 16(80%) recommended palivizumab use in preterm infants, 16(80%) recommended use in infants with CLD, 17(85%) congenital heart disease (CHD) and six (30%) bronchopulmonary dysplasia (BPD). Eight (40%) guidelines provided specific recommendations for immunocompromised infants. Canada, Western Australia, and American Academy of Paediatrics provided recommendations for Indigenous children. Frequency and dosage of palivizumab was universal across all CPGs. None of the international guidelines obtained were from low- or middle-income countries. Conclusions: Standardisation of CPGs may improve clinical decision making around use of palivizumab in high-risk infants.
26 Sep 2022Submitted to Pediatric Pulmonology
26 Sep 2022Submission Checks Completed
26 Sep 2022Assigned to Editor
04 Oct 2022Reviewer(s) Assigned
01 Dec 2022Review(s) Completed, Editorial Evaluation Pending
06 Dec 2022Editorial Decision: Revise Major
07 Jan 20231st Revision Received
11 Jan 2023Review(s) Completed, Editorial Evaluation Pending
11 Jan 2023Submission Checks Completed
11 Jan 2023Assigned to Editor
11 Jan 2023Reviewer(s) Assigned
16 Jan 2023Editorial Decision: Accept